Minos Biosciences incorporated
Spin-off from ESPCI Paris
Minos Biosciences BRIDGES MOLECULAR and CELL BIOLOGY in a manner never achieved before, allowing scientists to uncover the full picture of cell diversity and dynamics.
SINGLE-CELL REVOLUTION
Single-cell analysis is key to tackle cell diversity, and it has become in recent years an irreplaceable tool in all fields of biological and medical research.
Current single-cell technologies however, despite their remarkable progress, address only fragments of the puzzle – whereas combining multiple modes of single-cell analysis is essential to unlock the complexity of biology and reveal the complete picture.
MINOS SOLUTION
By combining MULTI-OMICS ANALYSIS with FUNCTIONAL ASSAYS at cell resolution and at high throughput, Minos’ solution provides a new paradigm in single-cell analysis that will open up new frontiers in life science research, precision medicine and diagnostics.
This is enabled using a breakthrough microfluidics concept to isolate cells combined with innovative approaches in imaging, molecular biology and also bioinformatics.
It will provide highly accurate insights into complex cell populations and their dynamics, opening up unique perspectives in a vast array of fundamental and translational research areas, as well as precision medicine – therapeutics and diagnostics.
MINOS IMPACT
Minos solution has the potential to tremendously impact major healthcare fields, such as:
Founded in January 2020 and incubated at the Institut Pierre-Gilles de Gennes in Paris (PC’up), Minos Biosciences emerged from several years of research and development in the interdisciplinary and highly innovative environment that characterize the ESPCI Paris – PSL engineering school and the research campus of Université PSL in Paris.
In early April 2021, Minos Biosciences closed a €1.5M financing round led by Elaia Partners via the PSL Innovation Fund.
In October 2021 and January 2022, Minos obtained an aggregated 1.7 M€ in public funding from BPI France, through the French Tech Seed and ADD (« Aide au développement deeptech ») programmes.
Later in 2023, Elaia Partners reinforced its confidence in our vision by leading a supplementary €1.5M financing round.
Partner at Elaia Partners
17 years in deeptech financing & investment
Independent Board member
CEO of CYTOO
20+ years experience in strategic marketing and business development
Co-founder
Professor at ESPCI Paris – PSL
World renowned single-cell expert & highly successful entrepreneur
Independent Board Member
CEO & Founder OncoDiag
Serial entrepreneur for 25+ years in the biotech & diagnostics field
Chief Executive Officer
Product Director
Co-founder
Scientific Director
Co-founder
Head of Data Science
University professor & hospital practitioner (PUPH) at Paris University and Aphorisme
Professor of pathology & hospital practitioner (PUPH) at Paris University
Professor at ESPCI Paris – PSL
World renowned single-cell expert & highly successful entrepreneur
Molecular systems, Director of Research CNRS at ESPCI Paris – PSL
Microfluidics, Professor at ESPCI Paris – PSL
Explore our open positions on Linkedin ➞
By email at
contact@minos.bio